home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

27.14 -0.58 (-2.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks ↗

November 14, 2023

You might not get a better chance to invest in these disruptive companies.

Via The Motley Fool

Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 13, 2023

Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.

Via Benzinga

Beam Therapeutics: Q3 Earnings Insights ↗

November 08, 2023

Via Benzinga

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

November 08, 2023

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble? ↗

October 25, 2023

Beam Therapeutics' pipeline will look slimmer going forward.

Via The Motley Fool

What's Going On With Beam Therapeutics Stock Thursday? ↗

October 19, 2023

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading lower Thursday.

Via Benzinga

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

November 08, 2023

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗

November 05, 2023

These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.

Via The Motley Fool

Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On ↗

November 01, 2023

Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.

Via InvestorPlace

Analyst Expectations for Beam Therapeutics's Future ↗

October 17, 2023

Via Benzinga

2 Cathie Wood Stocks I'm Bullish On ↗

October 05, 2023

These two next-gen biotechs could be outstanding buys for patient investors.

Via The Motley Fool

Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today ↗

October 31, 2023

Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology.

Via The Motley Fool

Verve Stock Soars On $250 Million Eli Lilly Deal ↗

October 31, 2023

Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs.

Via Investor's Business Daily

Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

October 31, 2023

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for...

Via Benzinga

Topics Intellectual Property

Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday ↗

October 31, 2023

U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy? ↗

October 31, 2023

Some of the strategic shifts proposed by management are for the better.

Via The Motley Fool

Why Beam Therapeutics Stock Is Getting Bought Today ↗

October 31, 2023

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's

Via Benzinga

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 31, 2023

Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Scoops Up More Than $3M Worth Of SoFi Technologies Shares Amid Q3 Earnings Beat From Online Lender ↗

October 30, 2023

Via Benzinga

Topics Earnings

5 Reasons Beam Therapeutics Remains a Risky Stock ↗

October 30, 2023

Shares of the gene-editing biotech might not have hit rock bottom yet.

Via The Motley Fool

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

October 25, 2023

From Beam Therapeutics

Via GlobeNewswire

Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

October 23, 2023

U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Beam Therapeutics Stock: Bear vs. Bull ↗

October 21, 2023

This biotech has a few factors in its corner, but it also faces a difficult path.

Via The Motley Fool

Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

October 19, 2023

Gainers

Via Benzinga

Investors Unpack Home Sales Data Ahead Of Fed Speech ↗

October 19, 2023

Stocks are lower across the board, as investors unpack this morning's jobs and manufacturing data and await commentary from Federal Reserve Chairman Jerome Powell.

Via Talk Markets

Topics Economy

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

October 19, 2023

From Beam Therapeutics

Via GlobeNewswire

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

1 Risky Biotech Stock to Consider Buying, and 1 to Avoid ↗

October 18, 2023

Both are in a race against time to commercialize a medicine before cash runs out.

Via The Motley Fool

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? ↗

October 03, 2023

The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com